Literature DB >> 15161648

Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis.

Alexander A Parikh1, Fan Fan, Wen Biao Liu, Syed A Ahmad, Oliver Stoeltzing, Niels Reinmuth, Diane Bielenberg, Corazon D Bucana, Michael Klagsbrun, Lee M Ellis.   

Abstract

Neuropilin-1 (NRP-1), a recently identified co-receptor for vascular endothelial growth factor, is expressed by several nongastrointestinal tumor types and enhances prostate cancer angiogenesis and growth in preclinical models. We investigated the expression and regulation of NRP-1 and the effect of NRP-1 overexpression on angiogenesis and growth of human colon adenocarcinoma by immunohistochemistry and in situ hybridization. NRP-1 was expressed in 20 of 20 human colon adenocarcinoma specimens but not in the adjacent nonmalignant colonic mucosa. By reverse transcriptase-polymerase chain reaction analysis, NRP-1 mRNA was expressed in seven of seven colon adenocarcinoma cell lines. Subcutaneous xenografts of stably transfected KM12SM/LM2 human colon cancer cells overexpressing NRP-1 led to increased tumor growth and angiogenesis in nude mice. In in vitro assays, conditioned medium from NRP-1-transfected cell lines led to an increase in endothelial cell migration, but did not affect endothelial cell growth. Epidermal growth factor (EGF) led to induction of NRP-1 in human colon adenocarcinoma cells and selective blockade of the epidermal growth factor receptor (EGFR) decreased constitutive and EGF-induced NRP-1 expression. Blockade of the Erk 1/2 and P38 mitogen-activated protein kinase signaling pathways also led to a decrease in constitutive and EGF-induced NRP-1 expression. These findings demonstrate the ubiquitous expression of NRP-1 in human colon cancer and suggest that NRP-1 may contribute to colon cancer angiogenesis and growth. This study also suggests that EGF and mitogen-activated protein kinase signaling pathways play an important role in NRP-1 regulation in colon cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161648      PMCID: PMC1615754          DOI: 10.1016/S0002-9440(10)63772-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  57 in total

1.  Preferential activation of the epidermal growth factor receptor in human colon carcinoma liver metastases in nude mice.

Authors:  C Parker; B J Roseman; C D Bucana; R Tsan; R Radinsky
Journal:  J Histochem Cytochem       Date:  1998-05       Impact factor: 2.479

2.  Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells.

Authors:  D J Price; T Miralem; S Jiang; R Steinberg; H Avraham
Journal:  Cell Growth Differ       Date:  2001-03

3.  Expression of vascular endothelial growth factor at the human gastric ulcer margin and in cultured gastric fibroblasts: a new angiogenic factor for gastric ulcer healing.

Authors:  M Takahashi; T Kawabe; K Ogura; S Maeda; Y Mikami; N Kaneko; A Terano; M Omata
Journal:  Biochem Biophys Res Commun       Date:  1997-05-19       Impact factor: 3.575

4.  Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer.

Authors:  Y Takahashi; S L Tucker; Y Kitadai; A N Koura; C D Bucana; K R Cleary; L M Ellis
Journal:  Arch Surg       Date:  1997-05

5.  Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165.

Authors:  S Soker; S Gollamudi-Payne; H Fidder; H Charmahelli; M Klagsbrun
Journal:  J Biol Chem       Date:  1997-12-12       Impact factor: 5.157

6.  Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis.

Authors:  R M Shaheen; W W Tseng; R Vellagas; W Liu; S A Ahmad; Y D Jung; N Reinmuth; K E Drazan; C D Bucana; D J Hicklin; L M Ellis
Journal:  Int J Oncol       Date:  2001-02       Impact factor: 5.650

7.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

8.  Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells.

Authors:  E Giraudo; L Primo; E Audero; H P Gerber; P Koolwijk; S Soker; M Klagsbrun; N Ferrara; F Bussolino
Journal:  J Biol Chem       Date:  1998-08-21       Impact factor: 5.157

9.  Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells.

Authors:  R Radinsky; S Risin; D Fan; Z Dong; D Bielenberg; C D Bucana; I J Fidler
Journal:  Clin Cancer Res       Date:  1995-01       Impact factor: 12.531

View more
  48 in total

1.  Osteocytes control myeloid cell proliferation and differentiation through Gsα-dependent and -independent mechanisms.

Authors:  Ehab Azab; Kevin Brown Chandler; Yuhei Uda; Ningyuan Sun; Amira Hussein; Raghad Shuwaikan; Veronica Lu; Catherine E Costello; Mark E McComb; Paola Divieti Pajevic
Journal:  FASEB J       Date:  2020-06-18       Impact factor: 5.191

2.  Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies.

Authors:  Sabrina Rizzolio; Gabriella Cagnoni; Chiara Battistini; Stefano Bonelli; Claudio Isella; Jo A Van Ginderachter; René Bernards; Federica Di Nicolantonio; Silvia Giordano; Luca Tamagnone
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

3.  Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.

Authors:  M J Gray; N A Dallas; G Van Buren; L Xia; A D Yang; R J Somcio; P Gaur; L S Mangala; P E Vivas-Mejia; F Fan; A M Sanguino; G E Gallick; G Lopez-Berestein; A K Sood; L M Ellis
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

4.  Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2.

Authors:  Silvia Coma; Akio Shimizu; Michael Klagsbrun
Journal:  Cell Adh Migr       Date:  2011-05-01       Impact factor: 3.405

5.  Neuropilin-1 (NRP-1)/GIPC1 pathway mediates glioma progression.

Authors:  Guilong Zhang; Lukui Chen; Kouhong Sun; Ahsan Ali Khan; Jianghua Yan; Hongyi Liu; Ailin Lu; Ning Gu
Journal:  Tumour Biol       Date:  2016-08-01

6.  Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells.

Authors:  Rajat Bhattacharya; Xiang-Cang Ye; Rui Wang; Xia Ling; Madonna McManus; Fan Fan; Delphine Boulbes; Lee M Ellis
Journal:  Cancer Res       Date:  2016-03-17       Impact factor: 12.701

7.  Neuropilin 1 Receptor Is Up-Regulated in Dysplastic Epithelium and Oral Squamous Cell Carcinoma.

Authors:  Shokoufeh Shahrabi-Farahani; Marina Gallottini; Fabiana Martins; Erik Li; Dayna R Mudge; Hironao Nakayama; Kyoko Hida; Dipak Panigrahy; Patricia A D'Amore; Diane R Bielenberg
Journal:  Am J Pathol       Date:  2016-02-11       Impact factor: 4.307

8.  Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation.

Authors:  Danny C W Yu; Jennifer S Waby; Haridasan Chirakkal; Carolyn A Staton; Bernard M Corfe
Journal:  Mol Cancer       Date:  2010-10-15       Impact factor: 27.401

9.  Metabolic stress induces the lysosomal degradation of neuropilin-1 but not neuropilin-2.

Authors:  Donggoo Bae; Shaolei Lu; Cherie A Taglienti; Arthur M Mercurio
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

10.  Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Authors:  Shumin Zhang; Haiyen E Zhau; Adeboye O Osunkoya; Shareen Iqbal; Xiaojian Yang; Songqing Fan; Zhengjia Chen; Ruoxiang Wang; Fray F Marshall; Leland W K Chung; Daqing Wu
Journal:  Mol Cancer       Date:  2010-01-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.